OptimizeRx (OPRX) Stock Price

OptimizeRx Price

NASDAQ·CLOSED
6.69USD+0.04 (+0.60 %)
Market closed

Revenue has compounded at 40.5% per year over the past 13 years to 92.13 M USD. OptimizeRx's net margin stands at -21.8%, down from -5.1% several years earlier. Analysts set a median price target of 24.48 USD, implying 265.9% above the current price. Of 13 analysts, 11 rate the stock a buy — an overall Buy consensus. The stock trades about 47% above its 52-week low.

OptimizeRx stock price

Volume
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of OptimizeRx over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how OptimizeRx stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing OptimizeRx's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

OptimizeRx Stock Price History
DateOptimizeRx Price
7/17/20266.69 USD
7/16/20266.65 USD
7/15/20266.65 USD
7/14/20266.53 USD
7/13/20266.52 USD
7/10/20266.41 USD
7/9/20266.28 USD
7/8/20265.96 USD
7/7/20266.29 USD
7/6/20266.29 USD
7/2/20266.19 USD
7/1/20266.08 USD
6/30/20265.72 USD
6/29/20265.43 USD
6/26/20265.12 USD
6/25/20264.90 USD
6/24/20264.74 USD
6/23/20264.54 USD
6/22/20264.81 USD
6/18/20264.98 USD
6/17/20265.08 USD
6/16/20265.28 USD
6/15/20265.32 USD
6/12/20265.23 USD
6/11/20265.28 USD
6/10/20265.08 USD
6/9/20265.07 USD
6/8/20265.05 USD
6/5/20265.11 USD
6/4/20265.38 USD
6/3/20264.95 USD
6/2/20265.28 USD
6/1/20265.38 USD
5/29/20265.19 USD
5/28/20265.10 USD
5/27/20264.88 USD
5/26/20264.83 USD
5/22/20264.94 USD
5/21/20264.94 USD
5/20/20264.97 USD
5/19/20264.83 USD
5/18/20265.09 USD
5/15/20265.21 USD
5/14/20265.30 USD
5/13/20264.92 USD
5/12/20266.34 USD
5/11/20266.21 USD
5/8/20266.44 USD
5/7/20266.63 USD
5/6/20266.47 USD
5/5/20266.63 USD
5/4/20266.77 USD
5/1/20266.70 USD
4/30/20266.23 USD
4/29/20266.14 USD
4/28/20266.40 USD
4/27/20266.41 USD
4/24/20266.43 USD
4/23/20266.45 USD
4/22/20266.80 USD
4/21/20266.94 USD
4/20/20267.20 USD
4/17/20267.17 USD
4/16/20266.64 USD
4/15/20266.40 USD
4/14/20266.05 USD
4/13/20265.93 USD
4/10/20266.13 USD
4/9/20266.16 USD
4/8/20266.50 USD
4/7/20266.65 USD
4/6/20266.80 USD
4/2/20266.56 USD
4/1/20266.56 USD
3/31/20266.28 USD
3/30/20266.46 USD
3/27/20266.60 USD
3/26/20266.96 USD
3/25/20267.18 USD
3/24/20266.78 USD
3/23/20266.43 USD
3/20/20265.99 USD
3/19/20266.15 USD
3/18/20266.31 USD
3/17/20266.62 USD
3/16/20266.53 USD
3/13/20266.40 USD
3/12/20265.93 USD
3/11/20266.67 USD
3/10/20266.58 USD
3/9/20266.84 USD
3/6/20266.74 USD
3/5/20267.53 USD
3/4/20267.87 USD
3/3/20267.32 USD
3/2/20267.39 USD
2/27/20267.58 USD
2/26/20267.84 USD
2/25/20267.79 USD
2/24/20267.64 USD
2/23/20267.37 USD
2/20/20268.20 USD
2/19/20268.63 USD
2/18/20268.38 USD
2/17/20268.29 USD
2/13/20268.75 USD
2/12/20268.21 USD
2/11/20269.23 USD
2/10/202610.07 USD
2/9/202610.35 USD
2/6/202610.89 USD
2/5/202610.54 USD
2/4/202611.02 USD
2/3/202610.25 USD
2/2/202610.92 USD
1/30/202610.76 USD
1/29/202610.82 USD
1/28/202610.97 USD
1/27/202611.77 USD
1/26/202611.64 USD
1/23/202611.92 USD
1/22/202611.96 USD
1/21/202611.66 USD
1/20/202611.94 USD
1/16/202612.15 USD
1/15/202612.60 USD
1/14/202612.85 USD
1/13/202612.63 USD
1/12/202614.06 USD
1/9/202613.16 USD
1/8/202613.36 USD
1/7/202613.85 USD
1/6/202613.32 USD
1/5/202613.17 USD
1/2/202612.42 USD
12/31/202512.26 USD
12/30/202512.39 USD
12/29/202512.25 USD
12/26/202512.48 USD
12/24/202512.76 USD
12/23/202512.74 USD
12/22/202513.29 USD
12/19/202513.51 USD
12/18/202513.60 USD
12/17/202513.11 USD
12/16/202512.77 USD
12/15/202513.18 USD
12/12/202513.36 USD
12/11/202514.03 USD
12/10/202513.87 USD
12/9/202513.91 USD
12/8/202514.01 USD
12/5/202514.24 USD
12/4/202514.65 USD
12/3/202514.32 USD
12/2/202514.11 USD
12/1/202514.34 USD
11/28/202515.27 USD
11/26/202515.38 USD
11/25/202515.39 USD
11/24/202515.29 USD
11/21/202514.59 USD
11/20/202513.58 USD
11/19/202514.26 USD
11/18/202514.12 USD
11/17/202514.79 USD
11/14/202515.18 USD
11/13/202515.46 USD
11/12/202516.15 USD
11/11/202515.89 USD
11/10/202516.51 USD
11/7/202515.65 USD
11/6/202518.94 USD
11/5/202519.16 USD
11/4/202518.78 USD
11/3/202519.44 USD
10/31/202520.49 USD
10/30/202519.61 USD
10/29/202520.56 USD
10/28/202521.04 USD
10/27/202520.88 USD
10/24/202521.68 USD
10/23/202519.59 USD
10/22/202518.82 USD
10/21/202519.84 USD
10/20/202520.30 USD
10/17/202519.55 USD
10/16/202519.78 USD
10/15/202520.39 USD
10/14/202519.90 USD
10/13/202518.73 USD
10/10/202518.08 USD
10/9/202518.29 USD
10/8/202518.24 USD
10/7/202517.95 USD
10/6/202517.68 USD
10/3/202518.75 USD
10/2/202517.60 USD
10/1/202518.98 USD
9/30/202520.50 USD
9/29/202520.51 USD
9/26/202518.78 USD
9/25/202518.34 USD
9/24/202518.41 USD
9/23/202519.06 USD
9/22/202519.09 USD
9/19/202518.20 USD
9/18/202518.92 USD
9/17/202517.78 USD
9/16/202518.12 USD
9/15/202517.33 USD
9/12/202517.33 USD
9/11/202518.83 USD
9/10/202517.56 USD
9/9/202517.79 USD
9/8/202518.29 USD
9/5/202518.82 USD
9/4/202518.61 USD
9/3/202517.54 USD
9/2/202517.16 USD
8/29/202518.07 USD
8/28/202518.23 USD
8/27/202517.53 USD
8/26/202517.61 USD
8/25/202517.00 USD
8/22/202517.25 USD
8/21/202516.14 USD
8/20/202515.49 USD
8/19/202515.80 USD
8/18/202516.98 USD
8/15/202516.86 USD
8/14/202517.59 USD
8/13/202517.33 USD
8/12/202516.40 USD
8/11/202516.18 USD
8/8/202517.30 USD
8/7/202512.84 USD
8/6/202512.48 USD
8/5/202512.53 USD
8/4/202512.86 USD
8/1/202512.50 USD
7/31/202512.62 USD
7/30/202512.64 USD
7/29/202512.89 USD
7/28/202513.80 USD
7/25/202514.35 USD
7/24/202513.94 USD
7/23/202513.77 USD
7/22/202513.30 USD
7/21/202512.88 USD
Access this data via the Eulerpool API
Get Free API Key

OptimizeRx Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
43.31 M USD
-2.14 M USD
-2.21 M USD
Jan 1, 2021
61.29 M USD
360,000.00 USD
380,000.00 USD
Jan 1, 2022
62.45 M USD
-12.29 M USD
-11.44 M USD
Jan 1, 2023
71.52 M USD
-17.52 M USD
-17.57 M USD
Jan 1, 2024
92.13 M USD
-6.22 M USD
-20.11 M USD
Jan 1, 2025 (e)
110.34 M USD
5.69 M USD
14.23 M USD
Jan 1, 2026 (e)
122.84 M USD
8.10 M USD
16.70 M USD
Jan 1, 2027 (e)
135.63 M USD
11.58 M USD
19.96 M USD

OptimizeRx Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jul 20, 2026, 8:35 AM
 
REVENUEM USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEM USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
SHARESM
20122013201420152016201720182019202020212022202320242025e2026e2027e
1.004.006.007.007.0012.0021.0024.0043.0061.0062.0071.0092.00110.00122.00135.00
–300.0050.0016.67–71.4375.0014.2979.1741.861.6414.5229.5819.5710.9110.66
100.0050.0050.0042.8657.1441.6757.1462.5055.8157.3861.2959.1564.1364.1364.1364.13
1.002.003.003.004.005.0012.0015.0024.0035.0038.0042.0059.0070.5478.2486.58
––––-1.00-2.00–-3.00-2.00–-12.00-17.00-6.005.008.0011.00
––––-14.29-16.67–-12.50-4.65–-19.35-23.94-6.524.556.568.15
––-1.00–-1.00-2.00–-3.00-2.00–-11.00-17.00-20.0014.0016.0019.00
–––––100.00––-33.33––54.5517.65-170.0014.2918.75
4.744.807.468.199.909.8211.8613.3914.8317.6917.7817.1218.2918.2918.2918.29
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales OptimizeRx generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue OptimizeRx retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare OptimizeRx's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares OptimizeRx has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against OptimizeRx's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

OptimizeRx stock margins

The OptimizeRx margin analysis displays the gross margin, EBIT margin, as well as the profit margin of OptimizeRx. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for OptimizeRx.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
55.67 %
-4.94 %
-5.10 %
Jan 1, 2021
58.15 %
0.59 %
0.62 %
Jan 1, 2022
62.40 %
-19.68 %
-18.32 %
Jan 1, 2023
59.98 %
-24.50 %
-24.56 %
Jan 1, 2024
64.45 %
-6.75 %
-21.83 %
Jan 1, 2025 (e)
64.45 %
5.15 %
12.89 %
Jan 1, 2026 (e)
64.45 %
6.59 %
13.59 %
Jan 1, 2027 (e)
64.45 %
8.54 %
14.72 %

OptimizeRx Stock Revenue, EBIT, Earnings per Share

The OptimizeRx earnings per share therefore indicates how much revenue OptimizeRx has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
2.92 USD
-0.14 USD
-0.15 USD
Jan 1, 2021
3.46 USD
0.02 USD
0.02 USD
Jan 1, 2022
3.51 USD
-0.69 USD
-0.64 USD
Jan 1, 2023
4.18 USD
-1.02 USD
-1.03 USD
Jan 1, 2024
5.04 USD
-0.34 USD
-1.10 USD
Jan 1, 2025 (e)
5.92 USD
0.31 USD
0.76 USD
Jan 1, 2026 (e)
6.59 USD
0.44 USD
0.90 USD
Jan 1, 2027 (e)
7.28 USD
0.63 USD
1.07 USD

OptimizeRx business model & stock analysis

The OPTIMIZERx Corporation is an emerging US company that is pursuing a revolutionary approach to solving challenges in healthcare. The company was founded in 2006 and is headquartered in Rochester, Michigan. OPTIMIZERx initially started as a provider of discount incentives to improve medication management. They later developed an innovative E-Prescribing platform to ensure the quick and secure delivery of medications to patients. Their business model focuses on providing scalable platforms and services to simplify and improve patient data management and communication. OPTIMIZERx offers products such as eCoupon, SampleMD, OptimizeRx Digital Therapeutic Support, and OptimizeRx 360. These platforms and services are sold to pharmaceutical companies, doctors, patients, and pharmacies to help reduce costs and optimize business processes. The company is divided into different categories including E-Prescribing, Patient-Centered Support, Point-of-Care Services, and Channel and Content Management. Overall, OPTIMIZERx aims to improve healthcare services through innovative technology and has achieved significant milestones such as a strong customer base and sustainable financial foundation.

OptimizeRx SWOT Analysis

Strengths

OPTIMIZERx Corp has several key strengths that contribute to its success in the market. Firstly, the company offers innovative and leading-edge technology solutions in the healthcare industry, providing a competitive advantage over its competitors. Additionally, OPTIMIZERx Corp has established strong strategic partnerships with hospitals, healthcare providers, and pharmaceutical companies, enabling it to expand its customer base and enhance its product offerings. Furthermore, the company has a dedicated and skilled workforce, fostering a culture of innovation, collaboration, and customer-centricity.

Weaknesses

Despite its strengths, OPTIMIZERx Corp also faces certain weaknesses that can hinder its growth and market position. One notable weakness is the dependence on a limited number of major clients for a significant portion of its revenue. This vulnerability exposes the company to potential risks, such as losing key clients or facing pricing pressures. Moreover, OPTIMIZERx Corp operates in a highly competitive market, where disruptive technologies and emerging companies pose a threat to its market share. The company needs to continuously invest in research and development to stay ahead of the competition.

Opportunities

OPTIMIZERx Corp has identified several opportunities that can drive future growth and profitability. The increasing adoption of digital healthcare solutions presents a promising opportunity for the company to expand its customer base and enhance its product portfolio. Moreover, the growing focus on personalized medicine and patient-centric care provides a platform for OPTIMIZERx Corp to develop tailored and targeted solutions that address specific patient needs. Additionally, the company can explore strategic partnerships with telehealth providers, electronic health record vendors, and other stakeholders in the healthcare ecosystem to leverage synergies and expand its market reach.

Threats

OPTIMIZERx Corp operates in an industry that faces various threats, which can impact its operations and financial performance. One significant threat is the strict regulatory environment in the healthcare sector. Compliance with existing and new regulations can increase the company's operational costs, hinder product development, and slow down market penetration. Additionally, the constantly evolving technology landscape poses a threat, as competitors can develop similar or superior solutions, challenging OPTIMIZERx Corp's market position. Economic downturns and budget constraints in the healthcare industry can also lead to reduced spending on technology solutions, affecting the company's revenue.

OptimizeRx Segments

OptimizeRx Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

OptimizeRx historical P/E ratio, EBIT multiple, and P/S ratio

OptimizeRx annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

OptimizeRx shares outstanding

The number of shares of OptimizeRx was 18.29 M in 2025. This indicates how many shares OptimizeRx is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
14.83 M Stocks
Jan 1, 2021
17.69 M Stocks
Jan 1, 2022
17.78 M Stocks
Jan 1, 2023
17.12 M Stocks
Jan 1, 2024
18.29 M Stocks
Jan 1, 2025 (e)
18.29 M Stocks
Jan 1, 2026 (e)
18.29 M Stocks
Jan 1, 2027 (e)
18.29 M Stocks

OptimizeRx stock splits

In OptimizeRx's history, there have been no stock splits.

Current OptimizeRx forecasts and price targets in July 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy84.62 % (11)
Hold15.38 % (2)
Sell0.00 % (0)
12M Price Target
24.48
Last Price
6.69
Currency
USD
12M Return Potential
265.92 %
LTM Return
0 %

OptimizeRx Earnings Estimates

DateEPS estimateRevenue EstimateQuarterly report
8/6/20260.12USD20.61 MUSD2026 Q2
5/12/20260.00USD18.72 MUSD2026 Q1
5/11/20260.00USD18.72 MUSD2026 Q1
4/30/20260.00USD18.72 MUSD2026 Q1
3/5/20260.23USD31.72 MUSD2025 Q4
2/19/20260.23USD31.72 MUSD2025 Q4
11/13/20240.06USD25.50 MUSD2024 Q3
5/8/2024-0.07USD20.14 MUSD2024 Q1
2/21/20240.27USD26.10 MUSD2023 Q4
8/7/20230.08USD17.29 MUSD2023 Q2

EESG©

Eulerpool ESG Scorecard© for the OptimizeRx stock

63/100
23
Environment
87
Social
79
Governance
E

Environment

20
Scope 1 - Direct Emissions2.89
Scope 2 - Indirect emissions from purchased energy13.6
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions38.39
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees44
Percentage of women in management—
Percentage of Asian employees5.6
Share of Asian management—
Percentage of Hispanic/Latino employees6.4
Hispano/Latino Management share—
Percentage of Black employees3.2
Black Management Share—
Percentage of white employees82.4
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

OptimizeRx shareholder structure

% Name
8.09175%
Whetstone Capital Advisors, LLC
Whetstone Capital Advisors, LLC
7.42740%
Weintraub (Michael)
Weintraub (Michael)
5.86840%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
5.68192%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
4.24163%
Royce Investment Partners
Royce Investment Partners
3.37407%
William Blair & Company, L.L.C. (Research)
William Blair & Company, L.L.C. (Research)
...

OptimizeRx Executives and Management Board

MO

Ms. Marion Odence-Ford

(60)

General Legal Officer and Chief Human Resources Officer

Compensation2.48 M USD
ES

Mr. Edward Stelmakh

(59)

Chief Financial & Strategic Officer

Compensation1.01 M USD
SS

Mr. Stephen Silvestro

(47)

President, Chief Executive Officer, Director · since 2019

Compensation973,132.00 USD
LV

Ms. Lynn Vos

(69)

Independent Chairperson of the Board

Compensation248,999.00 USD
PS

Mr. Patrick Spangler

(69)

Independent Director

Compensation214,999.00 USD

OptimizeRx Supply Chain

OptimizeRx Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
15 companies
#Name1M3M6M1Y2YTrend
1
Merck
0.48
0.69
0.89
0.49
0.73
2
Medtronic
0.69
0.69
0.13
0.62
0.68
3
Molina Healthcare
0.76
0.74
-0.15
-0.36
0.54
4
Eli Lilly
0.09
-0.33
-0.52
-0.51
0.54
5
Amazon.com
Supplier
0.31
0.49
0.72
0.54
0.53
#Name1M3M6M1Y2YTrend
1
Amgen
-0.55
-0.14
-0.67
-0.71
-0.58
2
GlaxoSmithKline
0.66
-0.66
-0.62
-0.68
-0.20
3
Sanofi
0.59
-0.49
-0.80
-0.74
-0.13
4
Novartis
0.52
-0.87
-0.84
-0.42
-0.12
5
AstraZeneca
0.74
-0.51
-0.79
-0.49
-0.05

Frequently asked questions about OptimizeRx

Some of the main competitors of OPTIMIZERx Corp in the market include Updox, Allscripts Healthcare Solutions, and NextGen Healthcare.

All fundamentals and in-depth analysis of OptimizeRx

Our stock analysis for OptimizeRx stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of OptimizeRx. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

OptimizeRx Stock
OptimizeRx Revenue→
OptimizeRx Stock
OptimizeRx Net Income→
OptimizeRx Stock
OptimizeRx P/E→
OptimizeRx Stock
OptimizeRx P/S→
OptimizeRx Stock
OptimizeRx EBIT→
OptimizeRx Stock
OptimizeRx Dividend→
OptimizeRx Stock
OptimizeRx Directors Dealings→
OptimizeRx Stock
OptimizeRx Stocks→
OptimizeRx Stock
OptimizeRx Market capitalization→
OptimizeRx Stock
OptimizeRx Debt→
OptimizeRx Stock
OptimizeRx Liabilities→
OptimizeRx Stock
OptimizeRx Equity→
OptimizeRx Stock
OptimizeRx AAQS→
OptimizeRx Stock
OptimizeRx Employees→
OptimizeRx Stock
OptimizeRx ROE→
OptimizeRx Stock
OptimizeRx ROA→
OptimizeRx Stock
OptimizeRx ROCE→
OptimizeRx Stock
OptimizeRx News→
OptimizeRx Stock
OptimizeRx Analyst Price Targets→

Health Stocks

Option Care HealthOPKO HealthOptiPharm CoOPC Pharmaceutical JSCOptiscan ImagingOnyx HealthcareOptomed OyjONWARD MedicalOptus Pharmaceutical CoOno Pharmaceutical CoOpus GeneticsOnkure TherapeuticsAll Stocks A–Z →